Annovis Bio, Inc. (ANVS)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Annovis Bio, Inc. (ANVS)
Go deeper and ask any question about ANVS
Company Performance
Current Price
as of Sep 13, 2024$8.01
P/E Ratio
N/A
Market Cap
$104.56M
Description
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
Metrics
Overview
- HQMalvern, PA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerANVS
- Price$8.01-5.43%
Trading Information
- Market Cap$104.56M
- Float78.44%
- Average Daily Volume (1m)169,399
- Average Daily Volume (3m)1,756,915
- EPS-$4.51
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$5.02M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$7.76M
- EV$61.13M
- EV/RevenueN/A
- P/EN/A
- P/SN/A